Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TCR modulator

DRUG CLASS:

TCR modulator

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

MAGEA4 expression	Sarcoma	MAGEA4 expression	Sarcoma	ADP-A2M4 Sensitive: C2 – Inclusion Criteria ADP-A2M4 Sensitive : C2	ADP-A2M4 Sensitive: C2 – Inclusion Criteria ADP-A2M4 Sensitive : C2
HLA-A*02:01	Soft Tissue Sarcoma	HLA-A*02:01	Soft Tissue Sarcoma	TAEST16001 Sensitive: C2 – Inclusion Criteria TAEST16001 Sensitive : C2	TAEST16001 Sensitive: C2 – Inclusion Criteria TAEST16001 Sensitive : C2
KRAS G12V	Solid Tumor	KRAS G12V	Solid Tumor	AFNT-211 Sensitive: C2 – Inclusion Criteria AFNT-211 Sensitive : C2	AFNT-211 Sensitive: C2 – Inclusion Criteria AFNT-211 Sensitive : C2
CTAG1B expression	Synovial Sarcoma	CTAG1B expression	Synovial Sarcoma	TBI-1301 Sensitive: C2 – Inclusion Criteria TBI-1301 Sensitive : C2	TBI-1301 Sensitive: C2 – Inclusion Criteria TBI-1301 Sensitive : C2
HLA-A*02 + MAGEA10 expression	Non Small Cell Lung Cancer	HLA-A*02 + MAGEA10 expression	Non Small Cell Lung Cancer	ADP-A2M10 Sensitive: C3 – Early Trials ADP-A2M10 Sensitive : C3	ADP-A2M10 Sensitive: C3 – Early Trials ADP-A2M10 Sensitive : C3
HLA-A*02 + MAGEA4 expression	Soft Tissue Sarcoma	HLA-A*02 + MAGEA4 expression	Soft Tissue Sarcoma	ADP-A2M4 Sensitive: C3 – Early Trials ADP-A2M4 Sensitive : C3	ADP-A2M4 Sensitive: C3 – Early Trials ADP-A2M4 Sensitive : C3
HLA-A*02 + MAGEA4 expression	Ovarian Cancer	HLA-A*02 + MAGEA4 expression	Ovarian Cancer	IMC-C103C Sensitive: C3 – Early Trials IMC-C103C Sensitive : C3	IMC-C103C Sensitive: C3 – Early Trials IMC-C103C Sensitive : C3
HLA-A*02:01 + MAGEA4 expression	Synovial Sarcoma	HLA-A*02:01 + MAGEA4 expression	Synovial Sarcoma	ADP-A2M4 Sensitive: C3 – Early Trials ADP-A2M4 Sensitive : C3	ADP-A2M4 Sensitive: C3 – Early Trials ADP-A2M4 Sensitive : C3
HLA-A*02:01 + CTAG1B expression	Soft Tissue Sarcoma	HLA-A*02:01 + CTAG1B expression	Soft Tissue Sarcoma	TAEST16001 Sensitive: C3 – Early Trials TAEST16001 Sensitive : C3	TAEST16001 Sensitive: C3 – Early Trials TAEST16001 Sensitive : C3
CTAG1B expression + CTAG2 expression	Non Small Cell Lung Cancer	CTAG1B expression + CTAG2 expression	Non Small Cell Lung Cancer	GSK3377794 Sensitive: D – Preclinical GSK3377794 Sensitive : D	GSK3377794 Sensitive: D – Preclinical GSK3377794 Sensitive : D
HLA-A*02:01	Acute Myelogenous Leukemia	HLA-A*02:01	Acute Myelogenous Leukemia	BSB-1001 Sensitive: D – Preclinical BSB-1001 Sensitive : D	BSB-1001 Sensitive: D – Preclinical BSB-1001 Sensitive : D